Identification

Name
Nisoldipine
Accession Number
DB00401  (APRD00635)
Type
Small Molecule
Groups
Approved
Description

Nisoldipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nisoldipine prevents calcium-dependent smooth muscle contraction and subsequent vasoconstriction. Nisoldipine may be used in alone or in combination with other agents in the management of hypertension.

Structure
Thumb
Synonyms
  • isobutyl methyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
  • Nisoldipin
  • Nisoldipina
  • Nisoldipine
  • Nisoldipino
  • Nisoldipinum
External IDs
Bay K 5552
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
SularTablet, film coated, extended release25.5 mg/1OralPhysicians Total Care, Inc.2009-02-24Not applicableUs
SularTablet, film coated, extended release17 mg/1OralCovis Pharma2017-02-03Not applicableUs
SularTablet, film coated, extended release17 mg/1OralShionogi1995-02-02Not applicableUs
SularTablet, film coated, extended release8.5 mg/1OralCovis Pharma2017-02-03Not applicableUs
SularTablet, film coated, extended release8.5 mg/1OralShionogi1995-02-02Not applicableUs
SularTablet, film coated, extended release34 mg/1OralCovis Pharma2017-02-03Not applicableUs
SularTablet, film coated, extended release34 mg/1OralShionogi1995-02-02Not applicableUs59630 0503 10 nlmimage10 4f1627b1
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
NisoldipineTablet, film coated, extended release25.5 mg/1OralUnited Research Laboratories, Inc.2009-09-01Not applicableUs
NisoldipineTablet, film coated, extended release40 mg/1OralPhysicians Total Care, Inc.2008-08-29Not applicableUs
NisoldipineTablet, film coated, extended release20 mg/1OralMylan Pharmaceuticals2008-07-25Not applicableUs
NisoldipineTablet, film coated, extended release17 mg/1OralMylan Pharmaceuticals2011-01-28Not applicableUs00378 2097 01 nlmimage10 de3bef7f
NisoldipineTablet, film coated, extended release40 mg/1OralMylan Pharmaceuticals2008-07-25Not applicableUs
NisoldipineTablet, film coated, extended release17 mg/1OralPrasco, Laboratories2012-02-27Not applicableUs
NisoldipineTablet, film coated, extended release34 mg/1OralMylan Pharmaceuticals2011-01-28Not applicableUs00378 2099 01 nlmimage10 243c1250
NisoldipineTablet, film coated, extended release8.5 mg/1OralMylan Pharmaceuticals2011-01-28Not applicableUs
NisoldipineTablet, film coated, extended release17 mg/1OralUnited Research Laboratories, Inc.2009-09-01Not applicableUs00677 1979 01 nlmimage10 9b084de2
NisoldipineTablet, film coated, extended release34 mg/1OralUnited Research Laboratories, Inc.2009-09-01Not applicableUs
International/Other Brands
Baymycard (Bayer) / Baymycard RR (Bayer) / Bo Ping (Rui Yang Pharm) / Di Yi Xin (Tasly) / Ji Ni Le Er (Jiankang Pharmaceutical) / Ninobarucin (Choseido Pharmaceutical) / Nisomynard (Yoshindo) / Riohard (Taiyo Pharmaceutical) / Ruidi (Nanjing Sanrui Pharmaceutical Co.) / Sular / Syscor (Bayer)
Categories
UNII
4I8HAB65SZ
CAS number
63675-72-9
Weight
Average: 388.4144
Monoisotopic: 388.16343651
Chemical Formula
C20H24N2O6
InChI Key
VKQFCGNPDRICFG-UHFFFAOYSA-N
InChI
InChI=1S/C20H24N2O6/c1-11(2)10-28-20(24)17-13(4)21-12(3)16(19(23)27-5)18(17)14-8-6-7-9-15(14)22(25)26/h6-9,11,18,21H,10H2,1-5H3
IUPAC Name
3-methyl 5-(2-methylpropyl) 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
SMILES
COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OCC(C)C

Pharmacology

Indication

For the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.

Associated Conditions
Pharmacodynamics

Nisoldipine, a dihydropyridine calcium-channel blocker, is used alone or with an angiotensin-converting enzyme inhibitor, to treat hypertension, chronic stable angina pectoris, and Prinzmetal's variant angina. Nisoldipine is similar to other peripheral vasodilators. Nisoldipine inhibits the influx of extra cellular calcium across the myocardial and vascular smooth muscle cell membranes possibly by deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum. The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.

Mechanism of action

By deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, Nisoldipine inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.

TargetActionsOrganism
AVoltage-dependent L-type calcium channel subunit alpha-1C
inhibitor
Human
AVoltage-dependent calcium channel subunit alpha-2/delta-1
inhibitor
Human
AVoltage-dependent L-type calcium channel subunit beta-2
inhibitor
Human
AVoltage-dependent L-type calcium channel subunit alpha-1D
inhibitor
Human
AVoltage-dependent L-type calcium channel subunit alpha-1S
inhibitor
Human
Absorption

Relatively well absorbed into the systemic circulation with 87% of the radiolabeled drug recovered in urine and feces. The absolute bioavailability of nisoldipine is about 5%.

Volume of distribution
Not Available
Protein binding

99%

Metabolism

Pre-systemic metabolism in the gut wall, and this metabolism decreases from the proximal to the distal parts of the intestine. Nisoldipine is highly metabolized; 5 major urinary metabolites have been identified. The major biotransformation pathway appears to be the hydroxylation of the isobutyl ester. A hydroxylated derivative of the side chain, present in plasma at concentrations approximately equal to the parent compound, appears to be the only active metabolite and has about 10% of the activity of the parent compound. Cytochrome P450 enzymes are believed to play a major role in the metabolism of nisoldipine. The particular isoenzyme system responsible for its metabolism has not been identified, but other dihydropyridines are metabolized by cytochrome P450 IIIA4.

Route of elimination

Although 60-80% of an oral dose undergoes urinary excretion, only traces of unchanged nisoldipine are found in urine.

Half life

7-12 hours

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Nisoldipine Action PathwayDrug action
Nisoldipine Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbafunginThe therapeutic efficacy of Abafungin can be increased when used in combination with Nisoldipine.Investigational
AbemaciclibThe serum concentration of Abemaciclib can be increased when it is combined with Nisoldipine.Approved, Investigational
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Nisoldipine.Approved, Investigational
AceclofenacThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Aceclofenac.Approved, Investigational
AcemetacinThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
AcepromazineThe risk or severity of hypotension can be increased when Acepromazine is combined with Nisoldipine.Approved, Vet Approved
Acetylsalicylic acidThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Nisoldipine.Approved
AlbaconazoleThe therapeutic efficacy of Albaconazole can be increased when used in combination with Nisoldipine.Investigational
AlclofenacThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Alclofenac.Approved, Withdrawn
AlcuroniumNisoldipine may increase the neuromuscular blocking activities of Alcuronium.Experimental
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Nisoldipine.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Nisoldipine.Experimental, Investigational
AlfuzosinAlfuzosin may increase the hypotensive activities of Nisoldipine.Approved, Investigational
AliskirenNisoldipine may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Nisoldipine.Approved, Investigational
AlminoprofenThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Alminoprofen.Experimental
AlprenololNisoldipine may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Nisoldipine.Approved, Investigational
AmifostineNisoldipine may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Amiloride.Approved
AminophenazoneThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Aminophenazone.Approved, Withdrawn
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Nisoldipine.Approved, Investigational
AmitriptylineThe risk or severity of hypotension can be increased when Amitriptyline is combined with Nisoldipine.Approved
AmlodipineAmlodipine may increase the hypotensive activities of Nisoldipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Nisoldipine.Approved, Illicit
AmoxapineThe risk or severity of hypotension can be increased when Amoxapine is combined with Nisoldipine.Approved
Amphotericin BNisoldipine may decrease the nephrotoxic activities of Amphotericin B.Approved, Investigational
AmprenavirThe serum concentration of Amprenavir can be increased when it is combined with Nisoldipine.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Amyl Nitrite.Approved
AntipyrineThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Antipyrine.Approved, Investigational
AntrafenineThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Antrafenine.Approved
ApalutamideThe serum concentration of Nisoldipine can be decreased when it is combined with Apalutamide.Approved, Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Nisoldipine.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Nisoldipine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Apraclonidine.Approved
AprepitantThe serum concentration of Nisoldipine can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Nisoldipine.Approved, Investigational
Aripiprazole lauroxilThe risk or severity of hypotension can be increased when Aripiprazole lauroxil is combined with Nisoldipine.Approved, Investigational
ArotinololThe risk or severity of hypotension can be increased when Arotinolol is combined with Nisoldipine.Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Nisoldipine.Approved, Investigational
Ascorbic acidThe serum concentration of Ascorbic acid can be increased when it is combined with Nisoldipine.Approved, Nutraceutical
AsenapineThe risk or severity of hypotension can be increased when Asenapine is combined with Nisoldipine.Approved
AsunaprevirThe serum concentration of Asunaprevir can be increased when it is combined with Nisoldipine.Approved, Investigational, Withdrawn
AtazanavirThe serum concentration of Nisoldipine can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololAtenolol may increase the hypotensive activities of Nisoldipine.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Nisoldipine.Approved
AtracuriumNisoldipine may increase the neuromuscular blocking activities of Atracurium.Approved, Experimental, Investigational
Atracurium besylateNisoldipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AvanafilAvanafil may increase the antihypertensive activities of Nisoldipine.Approved
AvatrombopagThe serum concentration of Avatrombopag can be increased when it is combined with Nisoldipine.Approved, Investigational
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Nisoldipine.Approved, Investigational
AzapropazoneThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Azapropazone.Withdrawn
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Azilsartan medoxomil.Approved, Investigational
BalsalazideThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Balsalazide.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Nisoldipine.Experimental
BarbitalBarbital may increase the hypotensive activities of Nisoldipine.Illicit
BaricitinibThe serum concentration of Baricitinib can be increased when it is combined with Nisoldipine.Approved, Investigational
BarnidipineNisoldipine may increase the antihypertensive activities of Barnidipine.Approved
BelinostatThe serum concentration of Belinostat can be increased when it is combined with Nisoldipine.Approved, Investigational
BenazeprilNisoldipine may increase the hypotensive activities of Benazepril.Approved, Investigational
BenazeprilatNisoldipine may increase the hypotensive activities of Benazeprilat.Experimental
BendazacThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Bendazac.Experimental
BendroflumethiazideNisoldipine may increase the hypotensive activities of Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Nisoldipine.Withdrawn
BenorilateThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Benorilate.Experimental
BenoxaprofenThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Benoxaprofen.Withdrawn
BenzydamineThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Benzydamine.Approved
BepridilNisoldipine may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Nisoldipine.Approved, Vet Approved
BetaxololBetaxolol may increase the hypotensive activities of Nisoldipine.Approved, Investigational
BethanidineBethanidine may increase the hypotensive activities of Nisoldipine.Approved
BevantololThe risk or severity of hypotension can be increased when Bevantolol is combined with Nisoldipine.Approved
BietaserpineBietaserpine may increase the hypotensive activities of Nisoldipine.Experimental
BifonazoleThe therapeutic efficacy of Bifonazole can be increased when used in combination with Nisoldipine.Approved, Investigational
BimatoprostNisoldipine may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Nisoldipine.Approved
BisoprololNisoldipine may increase the hypotensive activities of Bisoprolol.Approved
BisoxatinThe therapeutic efficacy of Bisoxatin can be decreased when used in combination with Nisoldipine.Approved
BoceprevirThe serum concentration of Nisoldipine can be increased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Nisoldipine.Approved, Investigational
BosentanThe serum concentration of Nisoldipine can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Nisoldipine.Approved
BQ-123Nisoldipine may increase the hypotensive activities of BQ-123.Investigational
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Nisoldipine.Approved, Investigational
BretyliumNisoldipine may increase the hypotensive activities of Bretylium.Approved
BrexpiprazoleThe risk or severity of hypotension can be increased when Brexpiprazole is combined with Nisoldipine.Approved, Investigational
BrigatinibThe serum concentration of Nisoldipine can be decreased when it is combined with Brigatinib.Approved, Investigational
BromfenacThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Bromfenac.Approved
BromocriptineThe risk or severity of hypotension can be increased when Bromocriptine is combined with Nisoldipine.Approved, Investigational
BromperidolThe serum concentration of Bromperidol can be increased when it is combined with Nisoldipine.Approved, Investigational
BucindololThe risk or severity of hypotension can be increased when Bucindolol is combined with Nisoldipine.Investigational
BufexamacThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Bufexamac.Approved, Experimental
BumadizoneThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Bumadizone.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Bumetanide.Approved
BunazosinThe risk or severity of hypotension can be increased when Bunazosin is combined with Nisoldipine.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Nisoldipine.Approved, Investigational
BupranololNisoldipine may increase the hypotensive activities of Bupranolol.Approved
ButoconazoleThe therapeutic efficacy of Butoconazole can be increased when used in combination with Nisoldipine.Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Nisoldipine.Approved
CadralazineCadralazine may increase the hypotensive activities of Nisoldipine.Experimental
Calcium AcetateThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Calcium Acetate.Approved, Investigational
Calcium CarbonateThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
Calcium ChlorideThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Calcium lactate.Approved, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Calcium levulinate.Approved, Experimental
Calcium pangamateThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Calcium Phosphate.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Nisoldipine.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Nisoldipine.Approved
CandesartanNisoldipine may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilNisoldipine may increase the hypotensive activities of Candesartan cilexetil.Approved
CandoxatrilNisoldipine may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilNisoldipine may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe serum concentration of Nisoldipine can be decreased when it is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Carbaspirin calcium.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Nisoldipine.Approved, Investigational
CarboxymethylcelluloseThe therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Nisoldipine.Approved, Investigational
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Nisoldipine.Approved, Investigational
CaroxazoneCaroxazone may increase the hypotensive activities of Nisoldipine.Withdrawn
CarprofenThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Carprofen.Approved, Vet Approved, Withdrawn
CarteololNisoldipine may increase the hypotensive activities of Carteolol.Approved
CarvedilolThe risk or severity of hypotension can be increased when Carvedilol is combined with Nisoldipine.Approved, Investigational
Castor oilThe therapeutic efficacy of Castor oil can be decreased when used in combination with Nisoldipine.Approved, Investigational, Nutraceutical, Vet Approved
CelecoxibThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Celecoxib.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be increased when it is combined with Nisoldipine.Approved, Investigational
CeritinibThe serum concentration of Nisoldipine can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Nisoldipine.Approved, Withdrawn
Cerliponase alfaThe serum concentration of Cerliponase alfa can be increased when it is combined with Nisoldipine.Approved, Investigational
ChlorambucilThe serum concentration of Chlorambucil can be increased when it is combined with Nisoldipine.Approved
ChloroquineThe serum concentration of Chloroquine can be increased when it is combined with Nisoldipine.Approved, Investigational, Vet Approved
ChlorothiazideNisoldipine may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorpromazineThe risk or severity of hypotension can be increased when Chlorpromazine is combined with Nisoldipine.Approved, Investigational, Vet Approved
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Nisoldipine.Approved
Choline magnesium trisalicylateThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Choline magnesium trisalicylate.Approved
CicletanineNisoldipine may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilNisoldipine may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Nisoldipine.Approved, Investigational
CimetidineThe serum concentration of Nisoldipine can be increased when it is combined with Cimetidine.Approved, Investigational
CimicoxibThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Cimicoxib.Investigational
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Nisoldipine.Approved, Investigational
CisatracuriumNisoldipine may increase the neuromuscular blocking activities of Cisatracurium.Approved
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Nisoldipine.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Nisoldipine.Approved
ClarithromycinThe serum concentration of Nisoldipine can be increased when it is combined with Clarithromycin.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Clevidipine.Approved, Investigational
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Nisoldipine.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Nisoldipine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Nisoldipine.Approved, Investigational, Vet Approved
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Nisoldipine.Approved
ClonixinThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Clonixin.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Nisoldipine.Approved
CloranololNisoldipine may increase the hypotensive activities of Cloranolol.Experimental
ClotrimazoleThe serum concentration of Nisoldipine can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of hypotension can be increased when Clozapine is combined with Nisoldipine.Approved
CobicistatThe serum concentration of Nisoldipine can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Nisoldipine.Approved, Investigational
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Nisoldipine.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Nisoldipine.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be increased when it is combined with Nisoldipine.Approved
CopanlisibThe serum concentration of Copanlisib can be increased when it is combined with Nisoldipine.Approved, Investigational
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Nisoldipine.Approved
CryptenamineNisoldipine may increase the hypotensive activities of Cryptenamine.Approved
CurcuminThe serum concentration of Nisoldipine can be increased when it is combined with Curcumin.Approved, Investigational
CyclopenthiazideNisoldipine may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclosporineThe metabolism of Nisoldipine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideNisoldipine may increase the hypotensive activities of Cyclothiazide.Approved
CytarabineThe serum concentration of Cytarabine can be increased when it is combined with Nisoldipine.Approved, Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Nisoldipine.Approved
DabrafenibThe serum concentration of Nisoldipine can be decreased when it is combined with Dabrafenib.Approved, Investigational
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Nisoldipine.Approved, Investigational
DanazolThe metabolism of Nisoldipine can be decreased when combined with Danazol.Approved
DanthronThe therapeutic efficacy of Danthron can be decreased when used in combination with Nisoldipine.Approved, Investigational, Withdrawn
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Nisoldipine.Approved
DapiprazoleThe risk or severity of hypotension can be increased when Dapiprazole is combined with Nisoldipine.Approved
DarunavirThe serum concentration of Nisoldipine can be increased when it is combined with Darunavir.Approved
DasabuvirThe serum concentration of Dasabuvir can be increased when it is combined with Nisoldipine.Approved
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Nisoldipine.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Nisoldipine.Approved, Investigational
DeferasiroxThe serum concentration of Nisoldipine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelaprilNisoldipine may increase the hypotensive activities of Delapril.Investigational
DelavirdineThe serum concentration of Nisoldipine can be increased when it is combined with Delavirdine.Approved
DeserpidineNisoldipine may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Nisoldipine.Approved
DexamethasoneThe serum concentration of Nisoldipine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexibuprofenThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Dexibuprofen.Approved, Investigational
DexketoprofenThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Dexketoprofen.Approved, Investigational
DexmedetomidineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Dexmedetomidine.Approved, Vet Approved
DexniguldipineNisoldipine may increase the hypotensive activities of Dexniguldipine.Experimental
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Nisoldipine.Approved, Illicit, Investigational, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Nisoldipine.Approved
DiclofenacThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Diclofenamide.Approved, Investigational
DiethylnorspermineNisoldipine may increase the hypotensive activities of Diethylnorspermine.Investigational
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Nisoldipine.Approved, Investigational
DifenpiramideThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Difenpiramide.Experimental
DiflunisalThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Diflunisal.Approved, Investigational
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Nisoldipine.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Nisoldipine.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Nisoldipine.Approved, Investigational
DihydroergotamineThe risk or severity of hypotension can be increased when Dihydroergotamine is combined with Nisoldipine.Approved, Investigational
DiltiazemThe serum concentration of Nisoldipine can be increased when it is combined with Diltiazem.Approved, Investigational
DinutuximabThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Dinutuximab.Approved, Investigational
DipyridamoleDipyridamole may increase the antihypertensive activities of Nisoldipine.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Nisoldipine.Approved, Investigational
DocusateThe therapeutic efficacy of Docusate can be decreased when used in combination with Nisoldipine.Approved
DolutegravirThe serum concentration of Dolutegravir can be increased when it is combined with Nisoldipine.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Nisoldipine.Approved, Investigational, Vet Approved
DorzolamideNisoldipine may increase the hypotensive activities of Dorzolamide.Approved
DoxacuriumNisoldipine may increase the neuromuscular blocking activities of Doxacurium.Approved
DoxazosinThe risk or severity of hypotension can be increased when Doxazosin is combined with Nisoldipine.Approved
DoxepinThe risk or severity of hypotension can be increased when Doxepin is combined with Nisoldipine.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Nisoldipine.Approved, Investigational
DoxycyclineThe serum concentration of Nisoldipine can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe risk or severity of hypotension can be increased when Dronedarone is combined with Nisoldipine.Approved
DroperidolThe risk or severity of hypotension can be increased when Droperidol is combined with Nisoldipine.Approved, Vet Approved
DroxicamThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Droxicam.Withdrawn
DuloxetineNisoldipine may increase the orthostatic hypotensive activities of Duloxetine.Approved
EconazoleThe therapeutic efficacy of Econazole can be increased when used in combination with Nisoldipine.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Nisoldipine.Approved
EfavirenzThe serum concentration of Nisoldipine can be increased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe therapeutic efficacy of Efinaconazole can be increased when used in combination with Nisoldipine.Approved
EfonidipineNisoldipine may increase the hypotensive activities of Efonidipine.Approved, Investigational
ElagolixThe serum concentration of Elagolix can be increased when it is combined with Nisoldipine.Approved, Investigational
ElbasvirThe serum concentration of Elbasvir can be increased when it is combined with Nisoldipine.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Nisoldipine.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Empagliflozin.Approved
EnalaprilNisoldipine may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatNisoldipine may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Nisoldipine.Experimental
EnzalutamideThe serum concentration of Nisoldipine can be decreased when it is combined with Enzalutamide.Approved
EpanololNisoldipine may increase the hypotensive activities of Epanolol.Experimental
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Nisoldipine.Approved, Investigational
EpirizoleThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Epirizole.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Eplerenone.Approved
EpoprostenolEpoprostenol may increase the hypotensive activities of Nisoldipine.Approved
EprosartanNisoldipine may increase the hypotensive activities of Eprosartan.Approved
ErgotamineThe risk or severity of hypotension can be increased when Ergotamine is combined with Nisoldipine.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Nisoldipine.Approved, Investigational
ErtugliflozinThe serum concentration of Ertugliflozin can be increased when it is combined with Nisoldipine.Approved, Investigational
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Nisoldipine.Approved, Investigational, Vet Approved
EsatenololNisoldipine may increase the hypotensive activities of Esatenolol.Experimental
EsmololNisoldipine may increase the hypotensive activities of Esmolol.Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Nisoldipine.Approved, Investigational, Vet Approved
Estradiol acetateThe serum concentration of Estradiol acetate can be increased when it is combined with Nisoldipine.Approved, Investigational, Vet Approved
Estradiol benzoateThe serum concentration of Estradiol benzoate can be increased when it is combined with Nisoldipine.Approved, Investigational, Vet Approved
Estradiol cypionateThe serum concentration of Estradiol cypionate can be increased when it is combined with Nisoldipine.Approved, Investigational, Vet Approved
Estradiol dienanthateThe serum concentration of Estradiol dienanthate can be increased when it is combined with Nisoldipine.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Estradiol valerate can be increased when it is combined with Nisoldipine.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Nisoldipine.Approved, Investigational, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Nisoldipine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Etacrynic acid.Approved, Investigational
EthenzamideThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Ethenzamide.Experimental
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Nisoldipine.Approved
EtodolacThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Etofenamate.Approved, Investigational
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Nisoldipine.Approved
EtoricoxibThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Nisoldipine can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Nisoldipine.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Nisoldipine.Approved
FelbinacThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Felbinac.Experimental
FelodipineNisoldipine may increase the hypotensive activities of Felodipine.Approved, Investigational
FenbufenThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Fenbufen.Approved
FenoldopamNisoldipine may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Fenoprofen.Approved
FentiazacThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Fentiazac.Experimental
FenticonazoleThe therapeutic efficacy of Fenticonazole can be increased when used in combination with Nisoldipine.Experimental
FeprazoneThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Feprazone.Experimental
Ferulic acidNisoldipine may increase the hypotensive activities of Ferulic acid.Experimental
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Nisoldipine.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Nisoldipine.Approved, Investigational
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Nisoldipine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Nisoldipine.Approved, Investigational
FirocoxibThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Firocoxib.Experimental, Vet Approved
FloctafenineThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Floctafenine.Approved, Withdrawn
Fluciclovine (18F)The serum concentration of Fluciclovine (18F) can be increased when it is combined with Nisoldipine.Approved
FluconazoleThe serum concentration of Nisoldipine can be increased when it is combined with Fluconazole.Approved, Investigational
FlunixinThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Flunixin.Vet Approved
FlunoxaprofenThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Flunoxaprofen.Experimental
FlupentixolThe risk or severity of hypotension can be increased when Flupentixol is combined with Nisoldipine.Approved, Investigational, Withdrawn
FlurbiprofenThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Flurbiprofen.Approved, Investigational
FluticasoneThe serum concentration of Fluticasone can be increased when it is combined with Nisoldipine.Approved, Experimental, Investigational
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Nisoldipine.Approved
Fluticasone propionateThe serum concentration of Fluticasone propionate can be increased when it is combined with Nisoldipine.Approved
FlutrimazoleThe therapeutic efficacy of Flutrimazole can be increased when used in combination with Nisoldipine.Experimental
FluvoxamineThe metabolism of Nisoldipine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Nisoldipine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Nisoldipine can be increased when it is combined with Fosaprepitant.Approved
FosinoprilNisoldipine may increase the hypotensive activities of Fosinopril.Approved
FosinoprilatNisoldipine may increase the hypotensive activities of Fosinoprilat.Experimental
FosphenytoinThe serum concentration of Nisoldipine can be decreased when it is combined with Fosphenytoin.Approved, Investigational
FostamatinibFostamatinib may increase the antihypertensive activities of Nisoldipine.Approved, Investigational
FurazolidoneFurazolidone may increase the hypotensive activities of Nisoldipine.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Nisoldipine can be increased when it is combined with Fusidic Acid.Approved, Investigational
GallamineNisoldipine may increase the neuromuscular blocking activities of Gallamine.Experimental
Gallamine TriethiodideNisoldipine may increase the neuromuscular blocking activities of Gallamine Triethiodide.Approved
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Nisoldipine.Approved, Investigational
GlecaprevirThe serum concentration of Glecaprevir can be increased when it is combined with Nisoldipine.Approved, Investigational
GlycerinThe therapeutic efficacy of Glycerin can be decreased when used in combination with Nisoldipine.Approved, Investigational
Gramicidin DThe serum concentration of Gramicidin D can be increased when it is combined with Nisoldipine.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Nisoldipine.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Nisoldipine.Approved, Investigational, Withdrawn
GuacetisalThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Guacetisal.Experimental
GuanabenzNisoldipine may increase the hypotensive activities of Guanabenz.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Nisoldipine.Approved
GuanazodineNisoldipine may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineNisoldipine may increase the hypotensive activities of Guanethidine.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Nisoldipine.Approved, Investigational
GuanoclorNisoldipine may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzNisoldipine may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanNisoldipine may increase the hypotensive activities of Guanoxan.Experimental
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Nisoldipine.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Nisoldipine.Experimental
HexamethoniumNisoldipine may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Nisoldipine.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Nisoldipine.Experimental
HydralazineHydralazine may increase the hypotensive activities of Nisoldipine.Approved
HydrochlorothiazideNisoldipine may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Nisoldipine.Approved, Vet Approved
HydroflumethiazideNisoldipine may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
HydroxyureaThe serum concentration of Hydroxyurea can be increased when it is combined with Nisoldipine.Approved
IbuprofenThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Ibuprofen.Approved
IbuproxamThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Ibuproxam.Withdrawn
IcosapentThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Icosapent.Approved, Nutraceutical
IdelalisibThe serum concentration of Nisoldipine can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of hypotension can be increased when Iloperidone is combined with Nisoldipine.Approved
IloprostIloprost may increase the hypotensive activities of Nisoldipine.Approved, Investigational
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Nisoldipine.Approved
ImidaprilNisoldipine may increase the hypotensive activities of Imidapril.Investigational
Imidazole salicylateThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Imidazole salicylate.Experimental
ImipramineThe risk or severity of hypotension can be increased when Imipramine is combined with Nisoldipine.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Nisoldipine.Approved
IndapamideNisoldipine may increase the hypotensive activities of Indapamide.Approved
IndenololNisoldipine may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe serum concentration of Nisoldipine can be increased when it is combined with Indinavir.Approved
IndobufenThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Indobufen.Investigational
IndomethacinThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Indomethacin.Approved, Investigational
IndoprofenThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Indoprofen.Withdrawn
IndoraminThe risk or severity of hypotension can be increased when Indoramin is combined with Nisoldipine.Withdrawn
Inotuzumab ozogamicinThe serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Nisoldipine.Approved, Investigational
IproniazidIproniazid may increase the hypotensive activities of Nisoldipine.Withdrawn
IrbesartanNisoldipine may increase the hypotensive activities of Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Nisoldipine.Approved, Investigational
IsavuconazoleThe serum concentration of Nisoldipine can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Nisoldipine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Nisoldipine.Approved
IsoconazoleThe therapeutic efficacy of Isoconazole can be increased when used in combination with Nisoldipine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Nisoldipine.Approved, Vet Approved
IsoniazidThe metabolism of Nisoldipine can be decreased when combined with Isoniazid.Approved, Investigational
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Isosorbide Dinitrate.Approved, Investigational
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Isosorbide Mononitrate.Approved
IsoxicamThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Isoxsuprine.Approved, Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Nisoldipine.Approved, Investigational
ItraconazoleThe serum concentration of Nisoldipine can be increased when it is combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Nisoldipine can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Nisoldipine.Approved, Investigational, Vet Approved
IvosidenibThe serum concentration of Ivosidenib can be increased when it is combined with Nisoldipine.Approved, Investigational
KebuzoneThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Kebuzone.Experimental
KetanserinKetanserin may increase the hypotensive activities of Nisoldipine.Investigational
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Nisoldipine.Approved
KetoconazoleThe serum concentration of Nisoldipine can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Ketoprofen.Approved, Vet Approved
KetorolacThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Ketorolac.Approved
LabetalolThe risk or severity of hypotension can be increased when Labetalol is combined with Nisoldipine.Approved
LacidipineNisoldipine may increase the hypotensive activities of Lacidipine.Approved, Investigational
LactitolThe therapeutic efficacy of Lactitol can be decreased when used in combination with Nisoldipine.Investigational
LactuloseThe therapeutic efficacy of Lactulose can be decreased when used in combination with Nisoldipine.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Nisoldipine.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Nisoldipine.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Nisoldipine.Approved, Investigational
LatanoprostNisoldipine may increase the hypotensive activities of Latanoprost.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Nisoldipine.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Nisoldipine.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Nisoldipine.Approved, Investigational
LercanidipineNisoldipine may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LetermovirThe serum concentration of Letermovir can be increased when it is combined with Nisoldipine.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Nisoldipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Nisoldipine.Approved, Investigational
LevodopaNisoldipine may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Nisoldipine.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Nisoldipine.Approved, Investigational
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Nisoldipine.Approved, Investigational
LinaclotideThe therapeutic efficacy of Linaclotide can be decreased when used in combination with Nisoldipine.Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Nisoldipine.Approved
LinezolidLinezolid may increase the hypotensive activities of Nisoldipine.Approved, Investigational
LinsidomineNisoldipine may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilNisoldipine may increase the hypotensive activities of Lisinopril.Approved, Investigational
LofexidineNisoldipine may increase the hypotensive activities of Lofexidine.Approved, Investigational
LonazolacThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Lonazolac.Experimental
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Nisoldipine.Approved
LopinavirThe serum concentration of Nisoldipine can be increased when it is combined with Lopinavir.Approved
LornoxicamThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Lornoxicam.Approved, Investigational
LorpiprazoleThe serum concentration of Nisoldipine can be increased when it is combined with Lorpiprazole.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Nisoldipine.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Nisoldipine.Approved, Investigational
LoxoprofenThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Loxoprofen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Nisoldipine.Approved, Investigational
LuliconazoleThe serum concentration of Nisoldipine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Nisoldipine can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Lumiracoxib.Approved, Investigational
LusutrombopagThe serum concentration of Lusutrombopag can be increased when it is combined with Nisoldipine.Approved, Investigational
MacitentanNisoldipine may increase the hypotensive activities of Macitentan.Approved
Magnesium carbonateThe therapeutic efficacy of Magnesium carbonate can be decreased when used in combination with Nisoldipine.Approved, Investigational
Magnesium citrateThe therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Nisoldipine.Approved
Magnesium hydroxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Nisoldipine is combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Nisoldipine is combined with Magnesium oxide.Approved
Magnesium peroxideThe therapeutic efficacy of Magnesium peroxide can be decreased when used in combination with Nisoldipine.Experimental
Magnesium salicylateThe risk or severity of hypotension and neuromuscular blockade can be increased when Nisoldipine is combined with Magnesium salicylate.Approved
Magnesium sulfateThe risk or severity of hypotension and neuromuscular blockade can be increased when Nisoldipine is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineNisoldipine may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe therapeutic efficacy of Mannitol can be decreased when used in combination with Nisoldipine.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Nisoldipine.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Nisoldipine.Approved, Investigational
Meclofenamic acidThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Mefenamic acid.Approved
MefloquineThe serum concentration of Mefloquine can be increased when it is combined with Nisoldipine.Approved, Investigational
MelatoninMelatonin may decrease the antihypertensive activities of Nisoldipine.Approved, Nutraceutical, Vet Approved
MeloxicamThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Meloxicam.Approved, Vet Approved
MelphalanThe serum concentration of Melphalan can be increased when it is combined with Nisoldipine.Approved
MesalazineThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Mesalazine.Approved
MetamizoleThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Metamizole.Approved, Investigational, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Nisoldipine.Approved
MethoserpidineNisoldipine may increase the hypotensive activities of Methoserpidine.Experimental
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Nisoldipine.Approved
MethotrimeprazineThe risk or severity of hypotension can be increased when Methotrimeprazine is combined with Nisoldipine.Approved, Investigational
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nisoldipine.Approved
Methyl celluloseThe therapeutic efficacy of Methyl cellulose can be decreased when used in combination with Nisoldipine.Approved
MethyldopaNisoldipine may increase the hypotensive activities of Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Nisoldipine.Approved, Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Nisoldipine.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Nisoldipine.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Nisoldipine.Approved, Vet Approved
MetipranololNisoldipine may increase the hypotensive activities of Metipranolol.Approved
MetocurineNisoldipine may increase the neuromuscular blocking activities of Metocurine.Approved
Metocurine IodideNisoldipine may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Withdrawn
MetolazoneNisoldipine may increase the hypotensive activities of Metolazone.Approved
MetoprololMetoprolol may increase the hypotensive activities of Nisoldipine.Approved, Investigational
MetyrosineNisoldipine may increase the hypotensive activities of Metyrosine.Approved
MibefradilThe serum concentration of Nisoldipine can be increased when it is combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe metabolism of Nisoldipine can be decreased when combined with Miconazole.Approved, Investigational, Vet Approved
MifepristoneThe serum concentration of Nisoldipine can be increased when it is combined with Mifepristone.Approved, Investigational
MinaprineMinaprine may increase the hypotensive activities of Nisoldipine.Approved
Mineral oilThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Nisoldipine.Approved, Vet Approved
MinoxidilMinoxidil may increase the hypotensive activities of Nisoldipine.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Nisoldipine.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Nisoldipine.Investigational
MitomycinThe serum concentration of Mitomycin can be increased when it is combined with Nisoldipine.Approved
MitotaneThe serum concentration of Nisoldipine can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Nisoldipine.Approved, Investigational
MivacuriumNisoldipine may increase the neuromuscular blocking activities of Mivacurium.Approved
MoclobemideMoclobemide may increase the hypotensive activities of Nisoldipine.Approved, Investigational
ModafinilThe serum concentration of Nisoldipine can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilNisoldipine may increase the hypotensive activities of Moexipril.Approved
MofebutazoneThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Mofebutazone.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Nisoldipine.Approved, Investigational
MorniflumateThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Morniflumate.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Nisoldipine.Approved, Investigational
MoxidectinThe serum concentration of Moxidectin can be increased when it is combined with Nisoldipine.Approved, Investigational, Vet Approved
MoxonidineMoxonidine may increase the hypotensive activities of Nisoldipine.Approved, Investigational
MuzolimineNisoldipine may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Nisoldipine.Approved, Investigational
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Nisoldipine.Approved, Investigational
NabumetoneThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Nabumetone.Approved
NadololThe serum concentration of Nadolol can be increased when it is combined with Nisoldipine.Approved
NafcillinThe serum concentration of Nisoldipine can be decreased when it is combined with Nafcillin.Approved, Investigational
NaftopidilNisoldipine may increase the hypotensive activities of Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Nisoldipine.Approved
NaloxoneThe serum concentration of Nisoldipine can be increased when it is combined with Naloxone.Approved, Vet Approved
NaproxenThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Naproxen.Approved, Vet Approved
NebivololNisoldipine may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe serum concentration of Nisoldipine can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Nisoldipine can be increased when it is combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Neostigmine can be increased when it is combined with Nisoldipine.Approved, Vet Approved
NepafenacThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Nepafenac.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Nisoldipine can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe serum concentration of Nisoldipine can be decreased when it is combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Nisoldipine.Withdrawn
NicardipineThe risk or severity of hypotension can be increased when Nicardipine is combined with Nisoldipine.Approved, Investigational
NicergolineThe risk or severity of hypotension can be increased when Nicergoline is combined with Nisoldipine.Approved, Investigational
NicorandilNicorandil may increase the hypotensive activities of Nisoldipine.Approved, Investigational
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Nisoldipine.Approved
NifenazoneThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Nifenazone.Experimental
Niflumic AcidThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Niflumic Acid.Approved
NiguldipineThe risk or severity of hypotension can be increased when Niguldipine is combined with Nisoldipine.Experimental
NilotinibThe serum concentration of Nisoldipine can be increased when it is combined with Nilotinib.Approved, Investigational
NilvadipineNisoldipine may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Nimesulide.Approved, Investigational, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Nisoldipine.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Nisoldipine.Approved
NitrendipineNisoldipine may increase the hypotensive activities of Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Nisoldipine.Approved
NitroaspirinThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Nitroglycerin.Approved, Investigational
NitroprussideNisoldipine may increase the hypotensive activities of Nitroprusside.Approved, Investigational
Nitrous acidThe risk or severity of adverse effects can be increased when Nitrous acid is combined with Nisoldipine.Approved, Investigational
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Nisoldipine.Approved
NortriptylineThe risk or severity of hypotension can be increased when Nortriptyline is combined with Nisoldipine.Approved
NS-398The therapeutic efficacy of Nisoldipine can be decreased when used in combination with NS-398.Experimental
ObinutuzumabNisoldipine may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Nisoldipine.Withdrawn
OctreotideThe serum concentration of Octreotide can be increased when it is combined with Nisoldipine.Approved, Investigational
OdanacatibThe serum concentration of Odanacatib can be increased when it is combined with Nisoldipine.Investigational
OlanzapineThe risk or severity of hypotension can be increased when Olanzapine is combined with Nisoldipine.Approved, Investigational
OlaparibThe metabolism of Nisoldipine can be decreased when combined with Olaparib.Approved
OlmesartanOlmesartan may increase the hypotensive activities of Nisoldipine.Approved, Investigational
OlsalazineThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Olsalazine.Approved
OmapatrilatNisoldipine may increase the hypotensive activities of Omapatrilat.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Nisoldipine.Approved, Investigational
OmeprazoleThe serum concentration of Omeprazole can be increased when it is combined with Nisoldipine.Approved, Investigational, Vet Approved
OmoconazoleThe therapeutic efficacy of Omoconazole can be increased when used in combination with Nisoldipine.Experimental
OndansetronThe serum concentration of Ondansetron can be increased when it is combined with Nisoldipine.Approved
OxaprozinThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Oxaprozin.Approved
OxiconazoleThe therapeutic efficacy of Oxiconazole can be increased when used in combination with Nisoldipine.Approved
OxprenololNisoldipine may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Oxyphenbutazone.Approved, Withdrawn
OxyphenisatinThe therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Nisoldipine.Investigational, Withdrawn
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Nisoldipine.Approved, Vet Approved
PalbociclibThe serum concentration of Nisoldipine can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe risk or severity of hypotension can be increased when Paliperidone is combined with Nisoldipine.Approved
PancuroniumNisoldipine may increase the neuromuscular blocking activities of Pancuronium.Approved
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Nisoldipine.Approved, Investigational
PantoprazoleThe serum concentration of Pantoprazole can be increased when it is combined with Nisoldipine.Approved
PapaverineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Papaverine.Approved, Investigational
ParecoxibThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Nisoldipine.Approved
ParitaprevirThe serum concentration of Paritaprevir can be increased when it is combined with Nisoldipine.Approved, Investigational
Patent BlueThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Patent Blue.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Nisoldipine.Approved
PenbutololNisoldipine may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentaerithritylThe therapeutic efficacy of Pentaerithrityl can be decreased when used in combination with Nisoldipine.Experimental
PentazocineThe serum concentration of Pentazocine can be increased when it is combined with Nisoldipine.Approved, Vet Approved
PentobarbitalThe serum concentration of Nisoldipine can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
PentoliniumNisoldipine may increase the hypotensive activities of Pentolinium.Approved
PerindoprilNisoldipine may increase the hypotensive activities of Perindopril.Approved
PerindoprilatNisoldipine may increase the hypotensive activities of Perindoprilat.Experimental
PhenelzinePhenelzine may increase the hypotensive activities of Nisoldipine.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Nisoldipine.Withdrawn
PhenobarbitalThe serum concentration of Nisoldipine can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenolphthaleinThe therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Nisoldipine.Approved, Withdrawn
PhenothiazineThe serum concentration of Phenothiazine can be increased when it is combined with Nisoldipine.Vet Approved
PhenoxybenzamineThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Nisoldipine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Nisoldipine.Withdrawn
PhentolamineThe risk or severity of hypotension can be increased when Phentolamine is combined with Nisoldipine.Approved
PhenylbutazoneThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Phenylbutazone.Approved, Vet Approved
PhenytoinThe serum concentration of Nisoldipine can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PibrentasvirThe serum concentration of Pibrentasvir can be increased when it is combined with Nisoldipine.Approved, Investigational
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Nisoldipine.Approved
PinacidilPinacidil may increase the hypotensive activities of Nisoldipine.Approved
PindololNisoldipine may increase the hypotensive activities of Pindolol.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Nisoldipine.Approved, Investigational
PipecuroniumNisoldipine may increase the neuromuscular blocking activities of Pipecuronium.Approved
PirlindolePirlindole may increase the hypotensive activities of Nisoldipine.Approved
PiroxicamThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Piroxicam.Approved, Investigational
PirprofenThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Pirprofen.Experimental
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Nisoldipine.Approved
PitolisantThe serum concentration of Nisoldipine can be decreased when it is combined with Pitolisant.Approved, Investigational
PivhydrazinePivhydrazine may increase the hypotensive activities of Nisoldipine.Withdrawn
PizotifenThe risk or severity of hypotension can be increased when Pizotifen is combined with Nisoldipine.Approved
Plantago seedThe therapeutic efficacy of Plantago seed can be decreased when used in combination with Nisoldipine.Approved, Investigational
PlecanatideThe therapeutic efficacy of Plecanatide can be decreased when used in combination with Nisoldipine.Approved, Investigational
PolycarbophilThe therapeutic efficacy of Polycarbophil can be decreased when used in combination with Nisoldipine.Approved
Polyethylene glycolThe therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Nisoldipine.Approved, Vet Approved
PolythiazideNisoldipine may increase the hypotensive activities of Polythiazide.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Nisoldipine.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Nisoldipine.Approved, Investigational
PosaconazoleThe serum concentration of Nisoldipine can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
Potassium acetateThe therapeutic efficacy of Potassium acetate can be decreased when used in combination with Nisoldipine.Approved, Investigational
PractololNisoldipine may increase the hypotensive activities of Practolol.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Nisoldipine.Approved, Investigational
PranoprofenThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Pranoprofen.Experimental, Investigational
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Nisoldipine.Approved
PrazosinThe risk or severity of hypotension can be increased when Prazosin is combined with Nisoldipine.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Nisoldipine.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Nisoldipine.Approved, Vet Approved
PrimidoneThe serum concentration of Nisoldipine can be decreased when it is combined with Primidone.Approved, Vet Approved
ProglumetacinThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Proglumetacin.Experimental
PromazineThe risk or severity of hypotension can be increased when Promazine is combined with Nisoldipine.Approved, Vet Approved
PropacetamolThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Propacetamol.Approved, Investigational
PropericiazineThe risk or severity of hypotension can be increased when Propericiazine is combined with Nisoldipine.Approved, Investigational
PropiomazineThe risk or severity of hypotension can be increased when Propiomazine is combined with Nisoldipine.Approved
PropiverineThe risk or severity of hypotension can be increased when Propiverine is combined with Nisoldipine.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Nisoldipine.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Nisoldipine.Approved, Investigational
PropyphenazoneThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Propyphenazone.Experimental
ProquazoneThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Proquazone.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Nisoldipine.Approved
QuetiapineThe risk or severity of hypotension can be increased when Quetiapine is combined with Nisoldipine.Approved
QuinaprilNisoldipine may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinaprilatNisoldipine may increase the hypotensive activities of Quinaprilat.Experimental
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Nisoldipine.Approved, Investigational
QuinineThe serum concentration of Nisoldipine can be decreased when it is combined with Quinine.Approved
RamiprilRamipril may increase the hypotensive activities of Nisoldipine.Approved
RamiprilatNisoldipine may increase the hypotensive activities of Ramiprilat.Experimental
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Nisoldipine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Nisoldipine.Approved, Investigational
RapacuroniumNisoldipine may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RasagilineRasagiline may increase the hypotensive activities of Nisoldipine.Approved
RavuconazoleThe therapeutic efficacy of Ravuconazole can be increased when used in combination with Nisoldipine.Investigational
RegorafenibThe serum concentration of Regorafenib can be increased when it is combined with Nisoldipine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Nisoldipine.Approved
RemikirenRemikiren may increase the hypotensive activities of Nisoldipine.Approved
RescinnamineNisoldipine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Nisoldipine.Approved, Investigational
Rhodamine 6GThe serum concentration of Rhodamine 6G can be increased when it is combined with Nisoldipine.Experimental
RibociclibThe serum concentration of Nisoldipine can be increased when it is combined with Ribociclib.Approved, Investigational
RifampicinThe serum concentration of Nisoldipine can be decreased when it is combined with Rifampicin.Approved
RifamycinThe serum concentration of Nisoldipine can be decreased when it is combined with Rifamycin.Investigational
RifapentineThe serum concentration of Nisoldipine can be decreased when it is combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Nisoldipine can be decreased when it is combined with Rifaximin.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Nisoldipine.Approved, Investigational
RimexoloneThe serum concentration of Nisoldipine can be decreased when it is combined with Rimexolone.Approved
RiociguatNisoldipine may increase the hypotensive activities of Riociguat.Approved
RisperidoneNisoldipine may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirThe serum concentration of Nisoldipine can be increased when it is combined with Ritonavir.Approved, Investigational
RituximabNisoldipine may increase the hypotensive activities of Rituximab.Approved
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Nisoldipine.Approved
RobenacoxibThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Robenacoxib.Experimental, Vet Approved
RocuroniumNisoldipine may increase the neuromuscular blocking activities of Rocuronium.Approved
RofecoxibThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Rofecoxib.Approved, Investigational, Withdrawn
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Nisoldipine.Approved, Investigational
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Nisoldipine.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Nisoldipine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Nisoldipine.Approved
RucaparibThe serum concentration of Rucaparib can be increased when it is combined with Nisoldipine.Approved, Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Nisoldipine.Approved
SafinamideSafinamide may increase the hypotensive activities of Nisoldipine.Approved, Investigational
SafrazineSafrazine may increase the hypotensive activities of Nisoldipine.Withdrawn
SalicylamideThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Salicylamide.Approved
Salicylic acidThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Salicylic acid.Approved, Investigational, Vet Approved
SalsalateThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Salsalate.Approved
SaprisartanNisoldipine may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirThe serum concentration of Nisoldipine can be increased when it is combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Sarilumab.Approved, Investigational
SC-236The therapeutic efficacy of Nisoldipine can be decreased when used in combination with SC-236.Experimental, Investigational
SecobarbitalSecobarbital may increase the hypotensive activities of Nisoldipine.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Nisoldipine.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Nisoldipine.Approved
SennosidesThe therapeutic efficacy of Sennosides can be decreased when used in combination with Nisoldipine.Approved
SertaconazoleThe therapeutic efficacy of Sertaconazole can be increased when used in combination with Nisoldipine.Approved, Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Nisoldipine.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Nisoldipine.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Nisoldipine.Approved
SiltuximabThe serum concentration of Nisoldipine can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Nisoldipine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Nisoldipine.Approved
SirolimusThe serum concentration of Sirolimus can be increased when it is combined with Nisoldipine.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Nisoldipine.Approved, Investigational
SitaxentanNisoldipine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium phosphate, monobasicThe therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Nisoldipine.Approved
Sodium sulfateThe therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Nisoldipine.Approved, Vet Approved
Sodium tartrateThe therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Nisoldipine.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Nisoldipine.Approved
SomatostatinThe serum concentration of Somatostatin can be increased when it is combined with Nisoldipine.Approved, Investigational
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Nisoldipine.Approved, Investigational
SorbitolThe therapeutic efficacy of Sorbitol can be decreased when used in combination with Nisoldipine.Approved
SotalolThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Sotalol.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Nisoldipine.Approved, Investigational
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Nisoldipine.Experimental
SpiraprilNisoldipine may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Nisoldipine can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StanoloneThe serum concentration of Stanolone can be increased when it is combined with Nisoldipine.Illicit, Investigational
Stanolone acetateThe serum concentration of Stanolone acetate can be increased when it is combined with Nisoldipine.Experimental
StiripentolThe serum concentration of Nisoldipine can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Nisoldipine.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Nisoldipine.Approved, Investigational
SulconazoleThe therapeutic efficacy of Sulconazole can be increased when used in combination with Nisoldipine.Approved
SulfasalazineThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Sulfasalazine.Approved
SulindacThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Sulindac.Approved, Investigational
SumatriptanThe serum concentration of Sumatriptan can be increased when it is combined with Nisoldipine.Approved, Investigational
SunitinibThe serum concentration of Sunitinib can be increased when it is combined with Nisoldipine.Approved, Investigational
SuprofenThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Suprofen.Approved, Withdrawn
SuxibuzoneThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Suxibuzone.Experimental
TacrineThe serum concentration of Tacrine can be increased when it is combined with Nisoldipine.Investigational, Withdrawn
TadalafilTadalafil may increase the antihypertensive activities of Nisoldipine.Approved, Investigational
TalinololThe serum concentration of Talinolol can be increased when it is combined with Nisoldipine.Investigational
TalniflumateThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Talniflumate.Approved
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Nisoldipine.Approved
TamsulosinThe risk or severity of hypotension can be increased when Tamsulosin is combined with Nisoldipine.Approved, Investigational
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Nisoldipine.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Nisoldipine.Approved, Investigational
TegaserodThe therapeutic efficacy of Tegaserod can be decreased when used in combination with Nisoldipine.Approved, Investigational, Withdrawn
TelaprevirThe serum concentration of Nisoldipine can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe serum concentration of Nisoldipine can be increased when it is combined with Telithromycin.Approved
TelmisartanNisoldipine may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilNisoldipine may increase the hypotensive activities of Temocapril.Experimental, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Nisoldipine.Approved
TenidapThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Tenidap.Experimental
TeniposideThe serum concentration of Teniposide can be increased when it is combined with Nisoldipine.Approved
TenoxicamThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Tenoxicam.Approved
TepoxalinThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Tepoxalin.Vet Approved
TerazosinThe risk or severity of hypotension can be increased when Terazosin is combined with Nisoldipine.Approved
TerconazoleThe therapeutic efficacy of Terconazole can be increased when used in combination with Nisoldipine.Approved
TerfenadineThe serum concentration of Terfenadine can be increased when it is combined with Nisoldipine.Approved, Withdrawn
Testosterone propionateThe serum concentration of Testosterone propionate can be increased when it is combined with Nisoldipine.Approved, Investigational, Vet Approved, Withdrawn
TetracyclineThe serum concentration of Tetracycline can be increased when it is combined with Nisoldipine.Approved, Vet Approved
TetrahydropalmatineNisoldipine may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Nisoldipine.Approved, Investigational, Withdrawn
TheophyllineTheophylline may increase the antihypertensive activities of Nisoldipine.Approved
ThiamylalThiamylal may increase the hypotensive activities of Nisoldipine.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Nisoldipine.Approved, Vet Approved
ThioproperazineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Nisoldipine.Approved
ThioridazineThe risk or severity of hypotension can be increased when Thioridazine is combined with Nisoldipine.Approved, Withdrawn
Tiaprofenic acidThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Tiaprofenic acid.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Nisoldipine.Approved
TicrynafenNisoldipine may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe serum concentration of Timolol can be increased when it is combined with Nisoldipine.Approved
TinoridineThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Tinoridine.Investigational
TioconazoleThe therapeutic efficacy of Tioconazole can be increased when used in combination with Nisoldipine.Approved
TipranavirThe serum concentration of Nisoldipine can be increased when it is combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Tizanidine.Approved, Investigational
TocilizumabThe serum concentration of Nisoldipine can be decreased when it is combined with Tocilizumab.Approved
TocopherylquinoneNisoldipine may increase the hypotensive activities of Tocopherylquinone.Experimental, Investigational
TolazolineThe risk or severity of hypotension can be increased when Tolazoline is combined with Nisoldipine.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Nisoldipine.Approved, Withdrawn
Tolfenamic AcidThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
TolmetinThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Tolmetin.Approved
TolonidineNisoldipine may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Nisoldipine.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Nisoldipine.Approved
TopiramateThe serum concentration of Topiramate can be increased when it is combined with Nisoldipine.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Nisoldipine.Approved, Investigational
TorasemideTorasemide may increase the hypotensive activities of Nisoldipine.Approved
TrandolaprilNisoldipine may increase the hypotensive activities of Trandolapril.Approved
TranylcypromineTranylcypromine may increase the hypotensive activities of Nisoldipine.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Nisoldipine.Approved, Investigational
TravoprostTravoprost may increase the hypotensive activities of Nisoldipine.Approved
TrazodoneThe risk or severity of hypotension can be increased when Trazodone is combined with Nisoldipine.Approved, Investigational
TreprostinilTreprostinil may increase the hypotensive activities of Nisoldipine.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Nisoldipine.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Nisoldipine.Approved
TrichlormethiazideNisoldipine may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Nisoldipine.Approved, Investigational
TrimazosinThe risk or severity of hypotension can be increased when Trimazosin is combined with Nisoldipine.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Nisoldipine.Approved, Investigational
TrimipramineThe risk or severity of hypotension can be increased when Trimipramine is combined with Nisoldipine.Approved
Trolamine salicylateThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Trolamine salicylate.Approved
TroleandomycinThe serum concentration of Nisoldipine can be increased when it is combined with Troleandomycin.Approved
TubocurarineNisoldipine may increase the neuromuscular blocking activities of Tubocurarine.Approved
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Nisoldipine.Approved, Investigational, Nutraceutical
UdenafilUdenafil may increase the antihypertensive activities of Nisoldipine.Approved, Investigational
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Nisoldipine.Approved
UnoprostoneNisoldipine may increase the hypotensive activities of Unoprostone.Approved, Investigational
UrapidilThe risk or severity of hypotension can be increased when Urapidil is combined with Nisoldipine.Investigational
ValdecoxibThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Valdecoxib.Approved, Investigational, Withdrawn
ValinomycinThe serum concentration of Valinomycin can be increased when it is combined with Nisoldipine.Experimental
ValsartanValsartan may increase the hypotensive activities of Nisoldipine.Approved, Investigational
ValspodarThe serum concentration of Valspodar can be increased when it is combined with Nisoldipine.Investigational
VardenafilVardenafil may increase the antihypertensive activities of Nisoldipine.Approved
VecuroniumNisoldipine may increase the neuromuscular blocking activities of Vecuronium.Approved
VelpatasvirThe serum concentration of Velpatasvir can be increased when it is combined with Nisoldipine.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Nisoldipine.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Nisoldipine.Approved, Investigational
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Nisoldipine.Approved
VerapamilThe risk or severity of hypotension can be increased when Verapamil is combined with Nisoldipine.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Nisoldipine.Approved
VincamineNisoldipine may increase the hypotensive activities of Vincamine.Experimental
VincristineThe excretion of Vincristine can be decreased when combined with Nisoldipine.Approved, Investigational
VinflunineThe serum concentration of Vinflunine can be increased when it is combined with Nisoldipine.Approved, Investigational
VinorelbineThe serum concentration of Vinorelbine can be increased when it is combined with Nisoldipine.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Nisoldipine.Approved, Investigational
VoriconazoleThe serum concentration of Nisoldipine can be increased when it is combined with Voriconazole.Approved, Investigational
VoxilaprevirThe serum concentration of Voxilaprevir can be increased when it is combined with Nisoldipine.Approved, Investigational
XipamideNisoldipine may increase the hypotensive activities of Xipamide.Experimental
YohimbineYohimbine may decrease the antihypertensive activities of Nisoldipine.Approved, Investigational, Vet Approved
ZaltoprofenThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Zaltoprofen.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Nisoldipine.Approved
ZiprasidoneThe risk or severity of hypotension can be increased when Ziprasidone is combined with Nisoldipine.Approved
ZofenoprilNisoldipine may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Zomepirac.Withdrawn
ZuclopenthixolThe risk or severity of hypotension can be increased when Zuclopenthixol is combined with Nisoldipine.Approved, Investigational
Food Interactions
  • Do not take with grapefruit juice as this has been shown to interfere with nisoldipine metabolism, resulting in a mean increase in Cmax of about 3-fold (up to about 7-fold) and AUC of almost 2-fold (up to 5-fold).

References

Synthesis Reference

Massimo Ferrari, Marcello Ghezzi, Manuel Alberelli, Alberto Ambrosini, "Industrial process for the synthesis of isobutyl methyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridine dicarboxylate (nisoldipine)." U.S. Patent US20050240022, issued October 27, 2005.

US20050240022
General References
  1. Mielcarek J, Grobelny P, Szamburska O: The effect of beta-carotene on the photostability of nisoldipine. Methods Find Exp Clin Pharmacol. 2005 Apr;27(3):167-71. [PubMed:15834448]
  2. Missan S, Zhabyeyev P, Dyachok O, Jones SE, McDonald TF: Block of cardiac delayed-rectifier and inward-rectifier K+ currents by nisoldipine. Br J Pharmacol. 2003 Nov;140(5):863-70. Epub 2003 Oct 6. [PubMed:14530219]
  3. Hamilton SF, Houle LM, Thadani U: Rapid-release and coat-core formulations of nisoldipine in treatment of hypertension, angina, and heart failure. Heart Dis. 1999 Nov-Dec;1(5):279-88. [PubMed:11720635]
External Links
Human Metabolome Database
HMDB0014545
KEGG Drug
D00618
KEGG Compound
C07699
PubChem Compound
4499
PubChem Substance
46504546
ChemSpider
4343
BindingDB
50011689
ChEBI
76917
ChEMBL
CHEMBL1726
Therapeutic Targets Database
DAP000595
PharmGKB
PA450634
IUPHAR
2524
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Nisoldipine
ATC Codes
C08CA07 — Nisoldipine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers2
4CompletedTreatmentDiabetic Nephropathies1

Pharmacoeconomics

Manufacturers
  • Mylan pharmaceuticals inc
  • Shionogi pharma inc
Packagers
  • A-S Medication Solutions LLC
  • Atlantic Biologicals Corporation
  • Bayer Healthcare
  • Bryant Ranch Prepack
  • Heartland Repack Services LLC
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Physicians Total Care Inc.
  • Quality Care
  • Remedy Repack
  • Sciele Pharma Inc.
  • Shionogi Pharma Inc.
  • Skyepharma Production Sas
  • United Research Laboratories Inc.
Dosage forms
FormRouteStrength
Tablet, film coated, extended releaseOral20 mg/1
Tablet, film coated, extended releaseOral30 mg/1
Tablet, film coated, extended releaseOral40 mg/1
Tablet, film coated, extended releaseOral17 mg/1
Tablet, film coated, extended releaseOral25.5 mg/1
Tablet, film coated, extended releaseOral34 mg/1
Tablet, film coated, extended releaseOral8.5 mg/1
Prices
Unit descriptionCostUnit
Sular 25.5 mg 24 Hour tablet6.84USD tablet
Sular 34 mg 24 Hour tablet6.84USD tablet
Sular 17 mg 24 Hour tablet6.48USD tablet
Sular 34 mg tablet5.64USD tablet
Sular 17 mg tablet5.17USD tablet
Nisoldipine er 30 mg tablet5.07USD tablet
Nisoldipine er 40 mg tablet5.07USD tablet
Sular 10 mg tablet5.04USD tablet
Sular 8.5 mg 24 Hour tablet5.04USD tablet
Nisoldipine er 20 mg tablet4.65USD tablet
Sular 25.5 mg tablet4.35USD tablet
Sular 8.5 mg tablet4.13USD tablet
Sular 20 mg tablet3.37USD tablet
Sular 30 mg 24 Hour tablet3.23USD tablet
Sular 40 mg 24 Hour tablet3.23USD tablet
Sular 30 mg tablet3.1USD tablet
Sular 40 mg tablet2.61USD tablet
Sular 10 mg 24 Hour tablet2.36USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5626874No1994-11-302014-11-30Us
US5422123No1995-06-062012-06-06Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP3.26MASUMOTO,K ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.00577 mg/mLALOGPS
logP3.63ALOGPS
logP3.06ChemAxon
logS-4.8ALOGPS
pKa (Strongest Basic)5.32ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area110.45 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity105.91 m3·mol-1ChemAxon
Polarizability39.72 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9357
Blood Brain Barrier-0.947
Caco-2 permeable+0.6928
P-glycoprotein substrateSubstrate0.5548
P-glycoprotein inhibitor IInhibitor0.8824
P-glycoprotein inhibitor IIInhibitor0.9239
Renal organic cation transporterNon-inhibitor0.8925
CYP450 2C9 substrateNon-substrate0.7874
CYP450 2D6 substrateNon-substrate0.8929
CYP450 3A4 substrateSubstrate0.7366
CYP450 1A2 substrateInhibitor0.8782
CYP450 2C9 inhibitorInhibitor0.7826
CYP450 2D6 inhibitorNon-inhibitor0.9141
CYP450 2C19 inhibitorInhibitor0.7804
CYP450 3A4 inhibitorInhibitor0.8414
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8982
Ames testNon AMES toxic0.778
CarcinogenicityNon-carcinogens0.5782
BiodegradationNot ready biodegradable0.9335
Rat acute toxicity2.6277 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8882
hERG inhibition (predictor II)Non-inhibitor0.9175
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as dihydropyridinecarboxylic acids and derivatives. These are compounds containing a dihydropyridine moiety bearing a carboxylic acid group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyridines and derivatives
Sub Class
Hydropyridines
Direct Parent
Dihydropyridinecarboxylic acids and derivatives
Alternative Parents
Nitrobenzenes / Nitroaromatic compounds / Dicarboxylic acids and derivatives / Vinylogous amides / Enoate esters / Methyl esters / Amino acids and derivatives / Propargyl-type 1,3-dipolar organic compounds / Azacyclic compounds / Enamines
show 6 more
Substituents
Dihydropyridinecarboxylic acid derivative / Nitrobenzene / Nitroaromatic compound / Monocyclic benzene moiety / Dicarboxylic acid or derivatives / Benzenoid / Methyl ester / Enoate ester / Alpha,beta-unsaturated carboxylic ester / Vinylogous amide
show 23 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
C-nitro compound, diester, methyl ester, dihydropyridine (CHEBI:76917)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1C
Uniprot ID
Q13936
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1C
Molecular Weight
248974.1 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Hu H, Marban E: Isoform-specific inhibition of L-type calcium channels by dihydropyridines is independent of isoform-specific gating properties. Mol Pharmacol. 1998 May;53(5):902-7. [PubMed:9584217]
  3. Morel N, Buryi V, Feron O, Gomez JP, Christen MO, Godfraind T: The action of calcium channel blockers on recombinant L-type calcium channel alpha1-subunits. Br J Pharmacol. 1998 Nov;125(5):1005-12. [PubMed:9846638]
  4. Wei X, Pan S, Lang W, Kim H, Schneider T, Perez-Reyes E, Birnbaumer L: Molecular determinants of cardiac Ca2+ channel pharmacology. Subunit requirement for the high affinity and allosteric regulation of dihydropyridine binding. J Biol Chem. 1995 Nov 10;270(45):27106-11. [PubMed:7592963]
  5. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Plays an important role in excitation-...
Gene Name
CACNA2D1
Uniprot ID
P54289
Uniprot Name
Voltage-dependent calcium channel subunit alpha-2/delta-1
Molecular Weight
124566.93 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and ina...
Gene Name
CACNB2
Uniprot ID
Q08289
Uniprot Name
Voltage-dependent L-type calcium channel subunit beta-2
Molecular Weight
73579.925 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Striessnig, J. (2004). Ca 2+ channel blockers. In Encyclopedic reference of molecular pharmacology (pp. 201-207). Berlin: Springer. [ISBN:9783540298328]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity involved sa node cell action potential
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1D
Uniprot ID
Q01668
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1D
Molecular Weight
245138.75 Da
References
  1. Sinnegger-Brauns MJ, Huber IG, Koschak A, Wild C, Obermair GJ, Einzinger U, Hoda JC, Sartori SB, Striessnig J: Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms. Mol Pharmacol. 2009 Feb;75(2):407-14. doi: 10.1124/mol.108.049981. Epub 2008 Nov 24. [PubMed:19029287]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1S
Uniprot ID
Q13698
Uniprot Name
Voltage-dependent L-type calcium channel subunit alpha-1S
Molecular Weight
212348.1 Da
References
  1. Peterson BZ, Catterall WA: Allosteric interactions required for high-affinity binding of dihydropyridine antagonists to Ca(V)1.1 Channels are modulated by calcium in the pore. Mol Pharmacol. 2006 Aug;70(2):667-75. Epub 2006 May 4. [PubMed:16675661]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Takara K, Sakaeda T, Tanigawara Y, Nishiguchi K, Ohmoto N, Horinouchi M, Komada F, Ohnishi N, Yokoyama T, Okumura K: Effects of 12 Ca2+ antagonists on multidrug resistance, MDR1-mediated transport and MDR1 mRNA expression. Eur J Pharm Sci. 2002 Aug;16(3):159-65. [PubMed:12128170]

Drug created on June 13, 2005 07:24 / Updated on August 02, 2018 04:20